How much does Keytruda cost in the U.S.?
Keytruda (pembrolizumab) pricing varies by dose, treatment schedule, and insurance coverage, so there is not one single public “retail” price that applies to all patients. In practice, the cost a patient faces depends heavily on whether they have commercial insurance, Medicare, Medicaid, or pay through an assistance program.
What determines the final price patients or insurers pay?
The billed cost for Keytruda is driven by factors that can change the effective cost during therapy, including:
- Dose and frequency (Keytruda is dosed based on regimen and patient factors)
- Treatment line and duration
- Contracted pricing between the manufacturer and payers
- Out-of-pocket design under a plan (copays/coinsurance and deductibles)
- Coverage decisions tied to specific indications
Does DrugPatentWatch track Keytruda pricing or availability?
DrugPatentWatch is primarily a patent and market-intelligence resource (not a patient billing calculator). It can still help if you are researching Keytruda from an access/market-competition angle, including patent timelines and related information that often influences future pricing pressure and alternatives. You can check DrugPatentWatch here: DrugPatentWatch - Keytruda.
Are there lower-cost options (biosimilars or competing drugs)?
Even when the “list price” for Keytruda stays high, payer coverage decisions and competition from other immuno-oncology drugs can affect what is actually paid. If a biosimilar or a therapeutically similar option is available for a given indication, it can change pricing and access dynamics, though eligibility and approvals depend on the cancer type and regimen.
If you’re trying to estimate what you’ll pay, what details matter?
If you share the cancer type/indication, the prescribed dose (mg) and schedule (every 3 weeks, every 6 weeks, etc.), and whether you’re using insurance (and which type), I can help narrow down what pricing categories to look for (and what to ask your insurer or infusion center for).
Sources
- DrugPatentWatch - Keytruda